Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

27 Jan 2006

Abstract excerpt

The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16443686
DOI: 10.1073/pnas.0507493103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapyPMID 16443686Read ↗

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential TherapeuticsSemantic proximity Read ↗

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Semantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationSemantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsSemantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsSemantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.